Grifols (NASDAQ:GRFS) Rating Increased to Buy at StockNews.com

StockNews.com upgraded shares of Grifols (NASDAQ:GRFS – Get Rating) from a hold rating to a buy rating in a report issued on Monday.

A number of other equities research analysts have also recently issued reports on the stock. Morgan Stanley cut shares of Grifols from an overweight rating to an equal weight rating in a report on Friday, March 3rd. Barclays raised Grifols from an underweight rating to an equal weight rating in a report on Thursday, February 16th. Jefferies Financial Group raised Grifols from a hold rating to a buy rating in a research report on Wednesday, January 18th. Credit Suisse Group began coverage on shares of Grifols in a research report on Friday, November 25th. They issued a neutral rating on the stock. Finally, AlphaValue raised shares of Grifols to a buy rating in a report on Monday, February 6th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of Moderate Buy and a consensus price target of $12.52.

Grifols Stock Up 0.1 %

NASDAQ GRFS opened at $7.64 on Monday. The company has a current ratio of 2.38, a quick ratio of 0.74 and a debt-to-equity ratio of 1.18. Grifols has a 12-month low of $5.71 and a 12-month high of $13.34. The company has a 50 day moving average price of $9.18 and a two-hundred day moving average price of $8.05.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of GRFS. Regal Partners Ltd bought a new position in Grifols during the fourth quarter worth $678,000. CI Private Wealth LLC acquired a new stake in Grifols in the 4th quarter worth $93,000. Thomas White International Ltd. increased its holdings in shares of Grifols by 40.6% during the 4th quarter. Thomas White International Ltd. now owns 61,525 shares of the biotechnology company’s stock worth $523,000 after purchasing an additional 17,777 shares during the period. Schonfeld Strategic Advisors LLC acquired a new position in shares of Grifols during the fourth quarter valued at about $390,000. Finally, Morgan Stanley lifted its stake in shares of Grifols by 26.2% in the fourth quarter. Morgan Stanley now owns 1,827,980 shares of the biotechnology company’s stock valued at $15,538,000 after buying an additional 379,156 shares during the period. 14.41% of the stock is currently owned by institutional investors and hedge funds.

About Grifols

(Get Rating)

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy.